Nascent Biotech

Nascent Biotech Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies fo

Collaborate to Explore Pritumumab Antibody-Drug Conjugates
02/06/2024

Collaborate to Explore Pritumumab Antibody-Drug Conjugates

NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced t...

Address

San Diego, CA

Website

Alerts

Be the first to know and let us send you an email when Nascent Biotech posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Our Story Is Just Starting

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer. The company is based in San Diego, California.